• AJMCAJMC
  • Center for Biosimilars
Center for Biosimilars®
Center for Biosimilars®
Business Practice
View MoreBusinessDevelopmentLegalPolicyPracticeRegulatory
News
Media
All Videos
Insights
Interviews
Peer Exchange
Podcasts
Compendia
Bone Health
Dermatology
Diabetes
Gastroenterology
Hematology
Neurology
Oncology
Ophthalmology
Rare Disease
Respiratory
Rheumatology
Conferences
Conference Coverage
Conference Listing
CME/CE
Resources
Authors
Biosimilar Resources
Interactive Tools
Polls
WHEN CHOICE ARRIVES: Competition & Consequences
SubscribeBIOSIMILAR APPROVALS
  • About
  • Contact
  • Advisory Board
  • Do Not Sell My Information
  • Terms & Conditions
  • Privacy Policy

© 2023 MJH Life Sciences and Center for Biosimilars®. All rights reserved.

Advertisement
Business PracticeSee All >
  • Business
  • Development
  • Legal
  • Policy
  • Practice
  • Regulatory
  • About
  • Contact
  • Advisory Board
  • Do Not Sell My Information
  • Terms & Conditions
  • Privacy Policy
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and Center for Biosimilars®. All rights reserved.

Asembia

  1. home

Dr Sonia Oskouei Describes the Need for More Biosimilar Education for Ophthalmologists

May 8th 2022

Video

Although the United States is looking to be one of the first countries to market an ophthalmology biosimilar, more education is needed to convince ophthalmologists of the safety and efficacy of biosimilars, said Cardinal Health's Sonia T. Oskouei, PharmD, BCMAS, DPLA.

The US Is Entering Round 2 of Biosimilar Activity, Says Cardinal Health’s Oskouei

May 3rd 2022

Article

The United States is about to enter round 2 of biosimilar activity with a pipeline that expands biosimilars into new therapeutic areas, said Sonia Oskouei, PharmD, BCMAS, DPLA, vice president of biosimilars, Cardinal Health, during her presentation at Asembia’s Specialty Pharmacy Summit.

Advertisement
Advertisement